Aromha Brain Health Test: making early Alzheimer’s screening easy at home
Official title: Advancing the Commercialization of the Aromha Brain Health Test: Regulatory, Manufacturing, and Clinical Integration for National Deployment
Funded at Aromha, INC. · NIH-11406873 · Data updated 2026-11-12
A self-administered, bilingual smell and memory test helps identify early signs of cognitive decline in people at risk for Alzheimer’s disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aromha, INC. NIH-funded |
| Lab location | 1 site (Potomac, United States) |
| Project start | September 17, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,651,957 |
| NIH project number | 1SB1AG102179-01 |
| Project ID | NIH-11406873 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk for Alzheimer’s disease or related dementias who may benefit from early screening and monitoring.
✕Less likely to help
Individuals without any risk factors or preclinical cognitive changes may not benefit from this test.
What this research studies
This grant supports finalizing and deploying a self-guided odor identification tool called the Aromha Brain Health Test (ABHT) for early detection of cognitive changes linked to Alzheimer’s disease. The test is integrated with a HIPAA-compliant digital platform to provide automated scoring and secure data reporting, reducing the need for staff-led assessments. The project focuses on regulatory clearance, scalable manufacturing, and clinical integration so the test can be used widely in the community. By reaching people before memory symptoms appear, ABHT aims to enable timely decisions about care and participation in future therapies.
Why it matters
Potential benefit: If successful, ABHT could enable earlier, accessible screening for Alzheimer’s risk, informing timely medical care and trial enrollment.
How similar studies have gone: Previous validations showed strong clinical relevance and usability in older adults at risk for AD and related dementias.
Where this research is happening
-
Aromha, INC.
Potomac, United States Active
Researchers
- Principal investigator: Reineke, Sean — Aromha, INC.
- Study coordinator: Reineke, Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.